Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Teva Hopes For Revenue Growth For First Time Since 2017

Feb 08 2023

• By Jessica Merrill

turn around — Teva hopes to reverse years of revenue declines • Source: Shutterstock

Related Content

Alvotech Lines Up FDA Inspection Ahead Of Adalimumab Action

Jan 19 2023

Teva Targets Risperidone LAI In H1 2023 Following Earlier FDA Snub

Nov 07 2022

All Eyes On Amjevita, Amgen’s Humira Biosimilar And Sole 2023 Product Launch

Feb 01 2023

A Trough Year For Teva, With A Turning Point Targeted For 2020

Feb 13 2019

Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization

Nov 21 2022

Related Companies

Teva Pharmaceutical Industries Ltd.

Novartis AG

Johnson & Johnson

Alvotech

Amgen, Inc.

Additional Topics

Leadership Sales & Earnings Generic Drugs Growth Biosimilars Business Strategies BioPharmaceutical

More from Leadership

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.